APFP 2020 (Due to COVID-19, it has been postponed to 2021.)

A- | A+


Official Website http://2020apfp.com/program-at-a-glance_o.php?class_id=1
Event 2020 Asian Pacific Federation of Pharmacologists Conference 
Time May 4-7, 2020
Location Taipei, Taiwan
Early Bird Registration March 10, 2020
Online Registration April 10, 2020
On-site Registration September 27-29, 2020
Time and Venue for the
Opening Lecture
18:00-19:00, September 27, 2020
201 Meeting Room,2F, Taipei International Convention Center
Speaker Prof. Tasuku Honjo
2014 Tang Prize laureate in Biopharmaceutical Science
2018 Nobel Prize winner in Medicine or Physiology
Title Cancer Immunotherapy: Efficacy Improvement and Adverse Effect
Summary In 1992, Prof. Honjo discovered the checkpoint molecule PD-1 and the crucial role it plays in allowing cancer cells to evade the antitumor immune response. He and many other researchers have since successfully developed several antibodies targeting PD-1. One such antibody, nivolumab (Opdivo®), had produced complete or partial responses in patients with non-small-cell lung cancer, melanoma, and renal-cell carcinoma in clinical trials and has received its first FDA approval in 2014, opening a new chapter in cancer treatment and increasing the survival rates of cancer patients. He and Dr. James P. Allison were awarded the Tang Prize in 2014 and together they won the 2018 Nobel Prize in Physiology or Medicine.  In this lecture, he will share with the audience his research on immunotherapy.